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Abstract: Anthracycline anticancer drugs, such as doxorubicin (DOX), can induce cardiotoxicity
supposed to be related to mitochondrial damage. We have recently demonstrated that a branched-chain
amino acid (BCAA)-enriched mixture (BCAAem), supplemented with drinking water to middle-aged
mice, was able to promote mitochondrial biogenesis in cardiac and skeletal muscle. To maximally favor
and increase oxidative metabolism and mitochondrial function, here we tested a new original formula,
composed of essential amino acids, tricarboxylic acid cycle precursors and co-factors (named α5), in
HL-1 cardiomyocytes and mice treated with DOX. We measured mitochondrial biogenesis, oxidative
stress, and BCAA catabolic pathway. Moreover, the molecular relevance of endothelial nitric oxide
synthase (eNOS) and mechanistic/mammalian target of rapamycin complex 1 (mTORC1) was studied
in both cardiac tissue and HL-1 cardiomyocytes. Finally, the role of Krüppel-like factor 15 (KLF15), a
critical transcriptional regulator of BCAA oxidation and eNOS-mTORC1 signal, was investigated.
Our results demonstrate that the α5 mixture prevents the DOX-dependent mitochondrial damage
and oxidative stress better than the previous BCAAem, implying a KLF15/eNOS/mTORC1 signaling
axis. These results could be relevant for the prevention of cardiotoxicity in the DOX-treated patients.
Keywords: branched-chain amino acids; cardiomyocytes; doxorubicin; endothelial nitric oxide
synthase; Krüppel-like factor 15; mechanistic/mammalian target of rapamycin; mitochondria;
oxidative stress; peroxisome proliferator-activated receptor γ coactivator 1 α; tricarboxylic acid cycle
1. Introduction
Anthracyclines, such as doxorubicin (DOX), are widely used and highly successful anticancer
chemotherapeutics [1]. Unfortunately, DOX administration results in dose-dependent side effects to
non-cancer tissues, including the development of cardiomyopathy, in addition to dyspnea, exercise
intolerance, hepatotoxicity, and nephropathy [2]. The risk of cardiotoxicity is one of the greatest
limiting factors to the clinical use of this drug, resulting in both acute and chronic cardiovascular
events. Acute cardiac toxicity of DOX can develop within minutes to days after administration
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and normally is characterized by hypotension, arrhythmia, and most importantly left ventricular
failure [1,3,4]. Although the molecular mechanisms of these side effects are not fully understood,
also because DOX affects many different intracellular processes, increasing evidence suggests that the
primary mediator of cardiac damage by DOX is oxidative stress, with increased reactive oxygen species
(ROS)-dependent lipid peroxidation and reduced levels of antioxidants and sulfhydryl groups [1,5].
In particular, mitochondrial dysfunction plays a critical role, because DOX accumulates in mitochondria,
binding to the inner membrane lipid cardiolipin and complexing with respiratory chain proteins [5–7].
The high production of ROS then causes mitochondrial impairment, with reduced ATP synthesis,
and apoptosis of cardiac cells. Moreover, DOX decreases mitochondrial biogenesis as a result of
binding to topoisomerase IIβ and complexing to the promoters of Ppargc1a and Ppargc1b, which is
likely responsible for blocking transcription of mitochondrial genes [8]. Upregulation of manganese
superoxide dismutase (MnSOD or SOD2)—that transforms toxic superoxide into hydrogen peroxide
(H2O2) and diatomic oxygen—protects cardiac cells exposed to DOX acting as a free radical scavenger
in mitochondria [9]. Moreover, overexpression of glutathione peroxidase 1 (Gpx1), a cytosolic and
mitochondrial enzyme that reduces H2O2 and fatty acid hydroperoxides, prevents cardiotoxicity,
mitochondrial dysfunction and inhibition of respiratory complex 1 activity induced by DOX [10].
Calorie restriction (CR) prolongs lifespan by preventing inflammatory diseases, cardiovascular
disorders, and cancer. Increasing evidence emphasizes the relevance of proteins involved in
mitochondrial pathways to explain the health effects of CR, including peroxisome proliferator-activated
receptor γ coactivator 1 α (PGC-1α)—the master regulator of mitochondrial biogenesis [11].
Additionally, CR has been found to reduce cardiac dysfunction in rats treated with DOX [12]. Hence,
one could hypothesize to combine the CR regimen with DOX treatment protocols with the aim of
mitigating cardiotoxicity. However, it is unlikely that such a dietary regimen could be adopted for
patients affected by cancer; many researchers are focusing in fact on the development of CR mimetic
compounds that provide the benefits of dietary restriction without reducing calorie intake [13].
Recently, we have demonstrated that chronic (3 months) dietary supplementation with a
branched-chain amino acid-enriched mixture (BCAAem) promoted mitochondrial biogenesis in
cardiac and skeletal muscle of middle-aged mice, with marked reduction of oxidative stress and
lifespan extension [14]. These effects were mediated by endothelial nitric oxide synthase (eNOS) and
mechanistic/mammalian target of rapamycin (mTOR) signaling pathways [14]. To maximally favor
and increase oxidative metabolism and mitochondrial function, here we tested an original formula
composed of essential amino acids, tricarboxylic acid cycle intermediates, and co-factors (named
α5) and explored its effect in HL-1 cardiomyocytes and mice treated with DOX. As compared to
BCAAem, α5 supplementation was more effective in promoting protective effects on the DOX-induced
mitochondrial dysfunction. Thus, we extended these results in vivo in young mice exposed to acute
DOX treatment. Our findings confirm the occurrence of mitochondrial dysfunction after acute DOX,
demonstrate marked defensive validity of short-term (10 days) supplementation with the new α5
formula, and suggest that Krüppel-like factor 15 (KLF15), eNOS, and mTOR signaling pathways are
crucially involved in the action of this defender.
2. Materials and Methods
2.1. Cell Cultures and Treatments
The paper follows the rules of the Declaration of Helsinki. HL-1 cardiomyocytes were obtained
from W.C. Claycomb (Cat# SCC065, Millipore, Milan, Italy) and plated in fibronectin/gelatin-coated
flasks, grown to 70–80% confluence in Claycomb medium (Sigma-Aldrich, Milan, Italy) supplemented
with 100 µM norepinephrine (from a 10 mM norepinephrine [Sigma-Aldrich] stock solution dissolved
in 30 mM L-ascorbic acid [Sigma-Aldrich]), 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL
streptomycin and 10% fetal bovine serum (FBS, Sigma-Aldrich) [15,16]. MCF-7 human breast cancer
cell line was obtained from P. Limonta (Pharmacological and Biomolecular Sciences, University of
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Milan, Milan, Italy) and cultured in pH 7.4 DMEM, containing streptomycin (100 U/mL), penicillin
(200 mg/mL), and gentamicin (50 mg/mL), and supplemented with 10% FBS. Both cell types were
treated with 1% BCAAem or α5 for 48 h and 1 µM DOX for 16 h (Figure 1). The detailed composition
percentages of mixtures are shown in Table 1.
Figure 1. HL-1 cell treatment.
Table 1. BCAAem and α5 composition (relative percentage).
Composition (%) BCAAem α5
Leucine 30.01 31.0885
Lysine 19.58 16.9030
Isoleucine 15.00 10.3628
Valine 15.00 10.3628
Threonine 8.40 7.2540
Cysteine 3.60 3.1089
Histidine 3.60 3.1089
Phenylalanine 2.40 2.0726
Methionine 1.20 1.0363
Tyrosine 0.72 0.6218
Tryptophan 0.48 2.0726
Citric acid - 8.001
Succinic acid - 2.00
Malic acid - 2.00
Vitamin B1 - 0.004
Vitamin B6 - 0.0038
For the study of phospho-proteins, HL-1 cells were treated with 1% α5 for 2 h and 1 µM
DOX for the last 60 min. For Klf15, eNOS, and Raptor knockdown experiments, HL-1 cells were
transfected with 50–100 nm Klf15, eNOS, and Raptor siRNA SMARTpool (Dharmacon; Lafayette,
CO, USA) or siGENOME nontargeting siRNA using Dharmafect 1 transfection reagent. After 24 h
transfection, cells were treated with 1% α5 for 24 h and 1 µM DOX for 16 h. Transfection efficacy was
determined with siGLO-RISC-free non-targeting siRNA and siRNA uptake by fluorescence detection
(absorbance/emission 557/570). Proteins were then extracted for western blotting analysis.
2.2. Animals and Treatments
The experimental protocol used was approved by the Institutional Ethical Committee of Milan
University (n. 16/09) and complied with the National Animal Protection Guidelines. Forty male
C57BL6/J mice (9 weeks-old) were housed separately in clean polypropylene cages and divided into
four groups (Figure 2): (1) the control group (CTRL, n = 10 mice) fed with standard diet (4.3 kcal % fat,
18.8 kcal % protein, 76.9 kcal % carbohydrate; Laboratorio Dottori Piccioni, Gessate, Italy) and receiving
a single i.p. saline injection (vehicle); (2) the α5 group (n = 10 mice) fed with standard diet and α5
supplementation (1.5 mg/g body weight/day in drinking water) receiving a single i.p. saline injection
(vehicle). α5 mixture was dissolved in tap water, after calculating the average daily drinking volume 2
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weeks before the start of treatment and stored at 4 ◦C before daily administration; (3) the DOX group
(n = 10 mice) fed with standard diet and receiving i.p. DOX (Doxo-HCl from Sigma-Aldrich) injection
at 20 mg/kg, a dose that had been shown cardiotoxic [17–19]; and 4) the DOX plus α5 group (n = 10
mice) fed with standard diet and receiving i.p. 20 mg/kg DOX injection plus α5 supplementation
(1.5 mg/g body weight/day in drinking water). α5 supplementation was performed for 10 days, with
a 12 h light/12 h dark cycle at 22 ◦C in a quiet, temperature- and humidity-controlled room; single
dosing of DOX was performed on the third day before the end of α5 treatment (Figure 2).
Figure 2. In vivo mouse treatment.
Drinking volume, food intake, and body weight were checked twice weekly. At the end of the
treatment period, mice were sacrificed by cervical dislocation and hearts quickly removed and freshly
used (for oxygen consumption analysis) or frozen in liquid nitrogen and stored at −80 ◦C (for mtDNA,
mRNA, and protein level measurement, in addition to citrate synthase activity analysis).
2.3. Quantitative RT-PCR Analysis
Quantitative RT-PCRs were performed as previously described [16,20] with the iQ SybrGreenI
SuperMix (Bio-Rad; Segrate, Italy) on an iCycler iQ real-time PCR detection system (Bio-Rad). Briefly,
RNA was isolated from left ventricle using the RNeasy Tissue Mini Kit (Qiagen, Segrate, Italy) or
from HL-1 cells using the RNeasy Mini Kit (Qiagen). cDNA was synthesized using the iScript cDNA
Synthesis Kit (Bio-Rad Laboratories). Primers were designed with Beacon Designer 2.6 software from
Premier Biosoft International (Palo Alto, CA, USA) and are shown in Table 2.
Table 2. Primers for quantitative RT-PCR.
Gene Sense Primer (5′-3’) Antisense Primer (5′-3’) PCR Product (bp) Ta (◦C)
Cat CACTGACGAGATGGCACACTTTG TGGAGAACCGAACGGCAATAGG 173 60
COX IV TGGGACTATGACAAGAATGAGTGG TTAGCATGGACCATTGGATACGG 113 60
cyt c ATAGGGGCATGTCACCTCAAAC GTGGTTAGCCATGACCTGAAAG 172 60
eNOS AGCGGCTGGTACATGAGTTC GATGAGGTTGTCCTGGTGTCC 116 60
GPX1 TCTGGGACCTCGTGGACTG CACTTCGCACTTCTCAAACAATG 156 60
KLF15 ACACCAAGAGCAGCCACCTC TGAGATCGCCGGTGCCTTGA 130 60
mtDNA CCACTTCATCTTACCATTTA ATCTGCATCTGAGTTTAATC 106 54
NRF1 ACAGATAGTCCTGTCTGGGGAAA TGGTACATGCTCACAGGGATCT 99 60
PGC-1α ACTATGAATCAAGCCACTACAGAC TTCATCCCTCTTGAGCCTTTCG 148 60
SESN2 GCCCCTGAGAAGCTCCGCAA GAGTTCGGCCAGGGACCAGC 129 60
SOD1 GGCTTCTCGTCTTGCTCTC AACTGGTTCACCGCTTGC 153 60
SOD2 GCCTCCCAGACCTGCCTTAC GTGGTACTTCTCCTCGGTGGCG 131 60
TBP ACCCTTCACCAATGACTCCTATG TGACTGCAGCAAATCGCTTGG 186 60
Tfam AAGACCTCGTTCAGCATATAACATT TTTTCCAAGCCTCATTTACAAGC 104 60
18S CTGCCCTATCAACTTTCGATGGTAG CCGTTTCTCAGGCTCCCTCTC 100 60
Cat, catalase; COX IV, cytochrome c oxidase subunit IV; cyt c, cytochrome c; eNOS, endothelial nitric oxide
synthase; GPX1, glutathione peroxidase 1; KLF15, Krüppel-like factor 15; mtDNA, mitochondrial DNA; NRF1,
nuclear respiratory factor 1; PGC-1α, peroxisome proliferator-activated receptor γ coactivator 1-α; SESN2, sestrin 2;
SOD1, superoxide dismutase 1; SOD2, superoxide dismutase 2; TBP, TATA-binding protein; Tfam, mitochondrial
transcription factor A; 18S, 18S ribosomal RNA.
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The cycle number at which the various transcripts were detectable (threshold cycle, CT) was
compared to that of TBP, referred to as ∆CT. The relative gene level was expressed as 2-(∆∆CT), in which
∆∆CT equals the ∆CT of DOX-, α5-, or DOX plus α5-treated mice (or treated HL-1 cells) minus the
∆CT of the control mice (or untreated HL-1 cells).
2.4. Western Blot Analysis
Protein extracts were obtained from left ventricle with T-PER mammalian protein extraction
reagent (Pierce, ThermoScientific, Rockford, IL, USA) or from HL-1 cells in M-PER mammalian
protein extraction reagent (Pierce), as indicated by the manufacturer, in the presence of 1 mM NaVO4,
10 mM NaF and a cocktail of protease inhibitors (Sigma-Aldrich, Milan, Italy). Protein content was
determined by the bicinchoninic acid protein assay (BCA, Pierce, Euroclone, Milan, Italy), and 50 µg of
the protein extract was separated by SDS-PAGE under reducing conditions. The separated proteins
were then electrophoretically transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Segrate,
Italy) [16,21]. Proteins of interest were detected with specific antibodies: anti-COX IV (cytochrome c
oxidase subunit IV, Cell Signaling Technology Cat #4844, Euroclone, Milan, Italy), anti-cyt c (cytochrome
complex, Cell Signaling Technology Cat #4280), anti-PGC-1α (proliferator-activated receptor γ
coactivator 1α, Cell Signaling Technology Cat #2178), anti-phospho-AKT (Ser473) (Cell Signaling
Technology Cat #4060), anti-AKT (Cell Signaling Technology Cat #4685), anti-phospho-eNOS (Ser1177)
(phospho-endothelial nitric oxide synthase, Cell Signaling Technology Cat #9571), anti-eNOS (Cell
Signaling Technology Cat #9572), anti-phospho-S6 (Ser235/236) (phospho-S6, Cell Signaling Technology
Cat #4858), anti-S6 (Cell Signaling Technology Cat #2217), anti-phospho-mTOR (Ser2481) (Cell Signaling
Technology Cat#2974), anti-mTOR (Cell Signaling Technology Cat#2972), anti-phospho-BCKDH
(Ser293) (Abcam Cat #200577), anti-BCKDH (Abcam Cat #138460), and anti-GAPDH (1:1000, Cell
Signaling Technology Cat #2118) at 1:1000 dilution each. After the visualization of phospho-eNOS,
phospho-AKT, phospho-mTOR, phospho-S6, and anti-phospho-BCKDH the filters were stripped
with the RestoreTM western blot stripping buffer (Euroclone, Milan, Italy) and further used for the
visualization of total eNOS, total AKT, total mTOR, total S6, or total BCKDH. Immunostaining was
performed using horseradish peroxidase-conjugated anti-rabbit or anti-mouse immunoglobulin for 1 h
at room temperature. The protein was detected using SuperSignal substrate (Pierce, Euroclone, Milan,
Italy) and quantified by densitometry with ImageJ image analysis software.
2.5. Mitochondrial DNA
For mtDNA analysis, total DNA was extracted with a QIAamp DNA Extraction Kit (Qiagen).
mtDNA was amplified using primers specific for the mtDNA and normalized to the 18S gene
(Table 2) [14]. The mtDNA content was determined using qRT-PCR by measuring the threshold cycle
ratio (∆CT) of the mtDNA gene vs. that of a nuclear encoded gene (18S) in left ventricle of DOX-, α5-
or DOX plus α5-treated mice, in addition to control untreated mice [22,23].
2.6. Citrate Synthase Activity
The activity was measured spectrophotometrically at 412 nm at 30 ◦C in left ventricle extracts [24,25].
Tissue was added to buffer containing 0.1 mM 5,5-dithio-bis-(2-nitrobenzoic) acid, 0.5 mM oxaloacetate,
50 µM EDTA, 0.31 mM acetyl CoA, 5 mM triethanolamine hydrochloride, and 0.1 M Tris-HCl (pH 8.1).
Citrate synthase activity was expressed as nmol citrate produced per min per mg of protein. The data
were normalized to total protein content, which was determined by the bicinchoninic acid assay, as
reported above.
2.7. Oxygen Consumption
Oxygen consumption was measured as described [26,27]. Mitochondria were isolated from left
ventricle of control and treated-mice. Samples were analyzed at 37 ◦C in a gas-tight vessel equipped
with a Clark-type oxygen electrode (Rank Brothers Ltd., Bottisham, Cambridge, England) connected to
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a chart recorder. The oxygen electrode was calibrated assuming the concentration of oxygen in the
incubation medium as 200 µmol/L at 37 ◦C.
2.8. Mitochondrial Oxidative Stress
To investigate the mitochondrial oxidative stress, mitochondria were isolated using the Qproteome
Mitochondria isolation kit (Qiagen). Mitochondrial H2O2 release was measured in the presence of
horseradish peroxidase (HRP), using the Amplex Red Hydrogen Peroxide/Peroxidase Assay kit
(Molecular Probes, Monza, Italy). Fluorometric measures were made using a Fusion Universal
Microplate Analyzer (Packard/PerkinElmer, Milan, Italy) with excitation filter at 550 nm and emission
filter at 590 nm. H2O2 production, calculated from a standard curve, was expressed as nmol/ min/mg
protein as described [14]. Moreover, mitochondrial aconitase and SOD activity were measured as
previously described [28]. Briefly, the formation of NADPH was followed spectrophotometrically
(340 nm) at 25 ◦C (for aconitase activity), while SOD activity was measured with the Superoxide
Dismutase Assay Kit (Calbiochem, Milan, Italy). One unit of SOD activity was defined as the amount of
the enzyme needed to exhibit 50% dismutation of the superoxide radical. Finally, the oxidative
damage of DNA was measured as a further marker of oxidative stress. The highly sensitive
8-hydroxy-2’-deoxyguanosine (8-OHdG) Check ELISA Kit (JaICA, Hamamatsu, Japan) was used [29].
Measurements were carried out in accordance with the manufacturer’s protocol. Total DNA was
extracted using QIampDNAMini Kit (Qiagen) and digested with nuclease P1 and alkaline phosphatase
(Sigma). Quality and quantity of DNA were confirmed by a NanoDrop ND-1000 spectrophotometry
analysis. Absorbance of the ELISA reaction product was determined spectrophotometrically using
450 nm as the primary wave.
2.9. Viability Assay
HL-1 cell viability was assessed by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] reagent (Sigma). HL-1 were seeded into 96-well culture plates at density 20,000 cells/well
(100 µL). The purple formazan crystals were dissolved in 5% SDS/0.1 M HCl (100 µL/well), and the
absorbance was recorded on a microplate reader (EL×800, BioTek Instruments, Winooski, VT, USA) at
a wavelength of 570 nm. Each test was repeated at least four times in quadruplicates.
2.10. Acid Phosphatase Assay
To quantify MCF7 cell growth, acid phosphatase assay was used as described [30]. Briefly, MCF7
cells were placed in 96-well plates at 5000 to 20,000 cells per well density and treated with 1% α5
(for 48 h) and 1 µM DOX (for 16 h). Culture medium was removed and each well washed once with
phosphate-buffered saline (PBS, pH 7.2), and added with 100 µL buffer containing 0.1 M sodium acetate
(pH 5.0), 0.1% Titon X-100, and 5 mM p-nitrophenyl phosphatase (pNPP). Then, plates were placed
in a 37 ◦C incubator for 2 h. The reaction was stopped with the addition of 10 µL 1 N NaOH, and
color development was assessed at 405 nm. Non-enzymatic pNPP hydrolysis was measured in wells
without cells.
2.11. Statistical Analysis and Data Presentation
Statistical analysis was performed with a one-way ANOVA followed by Student-Newman-Keuls’
test or Student’s t-test. Data are presented as the means ± standard deviations (SD), unless otherwise
specified. A statistically significant difference was accepted at p < 0.05.
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3. Results
3.1. Specific Amino-Acid Mixtures Prevent Mitochondrial Dysfunction in HL-1 Cardiomyocytes Acutely
Exposed to DOX
To protect cardiomyocytes against DOX toxicity, we propose to correct the impaired mitochondrial
function and oxidative stress in HL-1 cells exposed to the chemotherapeutic. An optimal combination of
relevant metabolic precursors capable of maximally increase oxidative metabolism in HL-1 cardiomyocytes
was evaluated. Specifically, we tested the effect of different combinations of essential amino acids,
tricarboxylic acid cycle (TCA) precursors, and cofactors on differentiating HL-1 cells (Table 1). For this
screening, we treated for 48 h differentiating cardiomyocytes with 1) the specific mixture of essential
amino acids we previously described (i.e., BCAAem) or 2) a new specific mixture of essential amino
acids, TCA precursors, and cofactors (referred to as α5) (see Materials and Methods), with or without
DOX (Figure 1). While α5 (1% w/v) increased the mRNA levels of mitochondrial biogenesis markers in
HL-1 cells, including PGC-1α, nuclear respiratory factor 1 (NRF1), mitochondrial transcription factor A (Tfam),
cytochrome c (cyt c), and cytochrome c oxidase complex IV (COX IV) over the basal value, only PGC-1α
expression was statistically increased by BCAAem (Figure 3A). Conversely, the expression of these genes
was decreased, as expected, when cardiomyocytes were exposed to 1 µM DOX for 16 h (Figure 3A).
Notably, α5 supplementation prevented this DOX toxicity with a complete rescue of the gene expression
(Figure 3A). Except for cyt c and COX IV, BCAAem was unable to reverse the DOX effect with statistical
significance (Figure 3A). Hence, we chose to use the α5 mixture hereafter. Notably, Figure S1 shows that
TCA intermediates—citric acid, succinic acid, and malic acid supplemented individually or all together at
the same concentrations in α5—were unable to prevent the DOX-induced reduction of mitochondrial
biogenesis as well as to change the mitochondrial gene expression when supplemented alone (data not
shown). The protective capacity of α5 supplementation on mitochondrial health was also evident at the
protein level (e.g., COX IV and, with a trend, cyt c) (Figure 3B).
Additionally, the reduction of citrate synthase activity promoted by DOX exposure—which is an
index of reduced mitochondrial mass and function—was fully antagonized by α5 supplementation,
which raised the enzyme activity also when added alone to the HL-1 cells (Figure 3C). These healthy
effects of α5 on the DOX-induced mitochondrial damage were further confirmed by the reduction of
oxidative stress. When compared to untreated cells, H2O2 release (an index of mitochondrial superoxide
anion production) was markedly increased by DOX treatment; α5 supplementation prevented this
effect (Figure 4A). α5 reduced H2O2 release also when added alone. Accordingly, measurements of
mitochondrial ROS production (as assessed by the basal/total aconitase activity ratio) and ability to
eliminate superoxides through SOD activity demonstrated that α5 supplementation prevented the
oxidative stress induced by DOX, with beneficial effects also when added alone (Figure 4B,C). Because
oxidative stress ignites the anti-ROS defense system, we investigated the expression of anti-ROS
enzymes. In particular, the expression of glutathione peroxidase 1 (GPX1) and superoxide dismutase 1
(SOD1) genes was increased in DOX-treated compared to untreated HL-1 cells (Figure 4D), consistently
with the increase of ROS production [1,7].
This was confirmed by the higher amount of 8-hydroxy-2’-deoxyguanosine (8-OHdG), a marker of
oxidative DNA damage, in cells exposed to DOX (Figure 4E). The α5 supplementation in DOX-treated
cells was able to counteract ROS production as evidenced by reduced expression of both SOD1 and
GPX1 genes (Figure 4D) and by restored 8-OHdG production to amount observed in the untreated
cells (Figure 4E). Figure 4D shows moreover that α5 is more effective than BCAAem in the anti-ROS
protection. Together, these results support the notion that α5 mixture can prevent mitochondrial
damage induced by acute exposure to DOX in HL-1 cardiomyocytes. Notably, this might be of relevant
impact on cell survival. The DOX-induced death of HL-1 cells in fact was prevented by α5 mixture
when supplemented together (Figure S2). No effect was evident on the cell survival when HL-1 cells
were exposed to α5 alone (Figure S2).
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Figure 3. Specific amino-acid mixtures prevent mitochondrial dysfunction in HL-1 cardiomyocytes
acutely exposed to DOX. (A) Mitochondrial biogenesis marker expression: peroxisome
proliferator-activated receptor-γ coactivator 1α (PGC1-α), nuclear respiratory factor-1 (NRF1),
transcription factor A (Tfam), cytochrome c (cyt c), and cytochrome c oxidase subunit IV (COX
IV) mRNA levels were analysed by quantitative RT-PCR. Relative expression values for the untreated
(CTRL) cells were taken as 1.0 (n = 5 experiments). (B) COX IV and cyt c protein levels were detected by
immunoblot analysis. The relative values were determined by densitometric analysis relative to GAPDH
levels; values for untreated (CTRL) cells were taken as 1.0 (n = 5 experiments). (C) Citrate synthase
activity. The values were normalized to protein content (n = 3 experiments). * p < 0.05, ** p < 0.01, and
***p < 0.001 vs. untreated cells; † p < 0.01 vs. DOX-treated cells; § p < 0.01 vs. BCAAem-treated cells.
All data are presented as the mean ± SD.
Figure 4. α5 Supplementation prevents DOX-induced oxidative stress in HL-1 cardiomyocytes.
(A) Mitochondrial H2O2 release, (B) basal aconitase/total aconitase ratio, and (C) superoxide dismutase
activity (SOD) in HL-1 cells (n = 3 experiments). (D) superoxide dismutase 1 (SOD1) and glutathione
peroxidase 1 (GPX1) mRNA levels were analysed by quantitative RT-PCR. Relative expression values
for the untreated (CTRL) cells were taken as 1.0 (n = 5 experiments). (E) Total DNA oxidative damage
measured as 8-hydroxy-2’-deoxyguanosine (8-OHdG) production.
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3.2. α5 Mixture Prevents Mitochondrial Dysfunction in Heart of DOX-Treated Mice
To confirm the in vitro results, an acute in vivo DOX treatment was performed as described [19].
On the third day before the end of the α5 treatment—which was performed for 10 days—a single
i.p. injection of 20 mg/kg DOX was done (Figure 2). Table 3 shows that DOX treatment significantly
decreased body weight and heart weight as compared to the control group as expected [31], and this
might depend on its marked anorexigenic effect. α5 was unable to modify body weight, heart weight,
and food intake both when supplemented alone and with DOX (Table 3). On the contrary, while water
consumption in DOX-treated mice was unchanged compared to control animals, α5 increased water
intake either when supplemented alone or with DOX.
Table 3. Body weight, heart weight, food intake, and water consumption.
CTRL α5 DOX DOX + α5
Body weight (g)
Heart weight (g)
Food intake (g)
Water intake (g)
24.84 ± 1.3
0.12 ± 0.01
5.2 ± 0.41
6.1 ± 0.7
24.46 ± 2
0.11 ± 0.02
5.34 ± 0.7
8.24 ± 0.88 *
20.75 ± 0.82 *
0.085 ± 0.02 *
3.73 ± 0.6*
6.13 ± 1.0
20.46 ± 1.04 *
0.09 ± 0.02 *
3.59 ± 0.47 *
7.07 ± 1.3
Measurements were done in 10 mice per group. Values represent mean ± D.S. * p < 0.05 vs. controls (i.e.,
saline-injected mice).
The mRNA levels of mitochondrial biogenesis genes were reduced in the left ventricle of
DOX-treated mice as compared to the control group, confirming the previous results (Figure 5A) [7].
Beyond increasing PGC-1α, cyt c, and COX IV mRNA levels when supplemented alone, the α5 mixture
was able to prevent significantly the DOX-induced reduction of PGC-1α, Tfam, and cyt c (Figure 5A).
Mitochondrial mass and function, measured as mitochondrial DNA (mtDNA) amount, respiratory
proteins (particularly COX IV), and citrate synthase activity were lower in DOX-treated than in
saline-treated mice, and these reductions were prevented when the mice were supplemented with
α5 (Figure 5B–D). Moreover, the mitochondrial respiratory function was investigated by measuring
oxygen consumption rate (OCR) with Clark’s electrode in mitocondria isolated from the left ventricle
of the diverse treatment groups. Figure 5E shows that DOX injection decreased OCR, while α5
supplementation fully conserved the mitochondrial respiration of the DOX-treated mice. The amino
acid mixture increased OCR also when supplemented alone (Figure 5E). Finally, the results reported in
Figure 5F confirmed in ex vivo samples that the DOX augmented the expression of ROS defense enzymes,
including SOD1, SOD2, catalase, and GPX1, as reported previously [7], while the α5 supplementation
blocked almost completely this effect. No changes were seen in mice treated with α5 alone (Figure 5F).
Collectively, these findings suggest that α5 supplementation prevents the DOX-induced mitochondrial
toxicity in heart, at least in part, by promoting mitochondrial biogenesis and function, as well as by
reducing oxidative stress.
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Figure 5. α5 formula prevents mitochondrial dysfunction in left ventricle of DOX-treated mice.
(A,F) Mitochondrial biogenesis marker expression. (A) PGC1-α, NRF1, Tfam, cyt c, COX IV and (F)
SOD1, superoxide dismutase 2 (SOD2), catalase (Cat), and GPX1 mRNA levels were analysed by
quantitative RT-PCR. Relative expression values for the vehicle-treated (Veh) mice were taken as 1.0
(n = 5 experiments). (B) Mitochondrial DNA (mtDNA) amount was analyzed by quantitative RT-PCR.
Relative units were expressed in comparison to those for the Veh-treated mice which were taken as 1.0
(n = 5 experiments). (C) COX IV and cyt c protein levels were determined by immunoblot analysis.
The relative values were determined by densitometric analysis relative to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) levels; values for Veh-treated mice were taken as 1.0 (n = 5 experiments).
(D) Citrate synthase activity. The values were normalized to protein content (n = 3 experiments).
(E) Basal oxygen consumption rate. Mitochondria were isolated from left ventricle of mice treated or
not with DOX and α5. Oxygen consumption rates were normalized to mitochondrial protein amount
(n = 3 experiments). * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. Veh-treated mice; † p < 0.05 and †† p < 0.01
vs. DOX-treated mice. All data are presented as the mean ± SD.
3.3. Different Signaling Pathways are Implicated in the Protective Effects of α5 Supplementation
Because we and others found that specific amino-acid combinations improve mitochondrial
homeostasis in pathological conditions through eNOS and mTORC1 activity [14,25,32], we analyzed
these signaling pathways in the left ventricle of mice treated with DOX and α5. Figure 6A,B show
that DOX-injection decreased eNOS expression, yet only partially eNOS activity (i.e., (Ser1177)
phospho-eNOS to total eNOS ratio). Notably, the α5 supplementation fully neutralized these effects.
When supplemented alone the α5 mixture was able to increase eNOS expression (Figure 6A). Given
that the eNOS-dependent nitric oxide (NO) production is in turn known to regulate the mTOR
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complex 1 (mTORC1) signaling pathway, and that mTORC1 activity is necessary and sufficient for
(Ser1177)-eNOS phosphorylation in different cell types [14,29,33–35], we measured phosphorylation
of S6 as a downstream marker of the mTORC1 activation in our model. DOX treatment decreased
(Ser235/236) phospho-S6 to total S6 ratio in the left ventricle when compared to saline injection, while
the α5 supplementation at least partially prevented this effect (Figure 6C). No significant changes
were observed with α5 mixture when supplemented alone. Diverse physiological stimuli modulate
mTORC1 signaling by site-specific mTOR phosphorylation. Here we focused on mTORC1-associated
Ser2481 mTOR autophosphorylation—the amino acid-dependent activation of mTORC1 signaling that
monitors mTORC1 intrinsic catalytic activity in vivo [36]. Our data reveal a functional role for Ser2481
mTOR phosphorylation in DOX and α5 action, in which DOX reduced and α5 rescued this reduction
of the selective mTOR phosphorylation in heart (Figure 6D). mTOR phosphorylation was increased
also when α5 was added alone. Together, our results suggested that both eNOS and mTORC1 may
play a role in the effects of DOX and α5 treatment.
Figure 6. Different signaling pathways are implicated in the protective effects of α5 supplementation in
DOX-treated mice. (A,E,F) Gene expression. (A) Endothelial nitric oxide synthase (eNOS), (E) Sestrin2,
and (F) Krüppel-like factor 15 (KLF15) mRNA levels were analysed by quantitative RT-PCR. Relative
expression values of the vehicle (Veh)-treated mice were taken as 1.0 (n = 5 experiments). (B,C,D, and
G) Protein levels. (B) Phospho-eNOS, (C) phospho-S6, (D) phospho-mTOR, and (G) phospho-BCKDH
protein levels were detected by immunoblot analysis. The relative values were densitometrically
analyzed and reported as ratios to total eNOS, S6, mTOR, and BCKDH levels, respectively. Values for
Veh-treated mice were taken as 1.0 (n = 5 experiments). * p < 0.05 and ** p < 0.01 vs. Veh-treated mice; †
p < 0.05 vs. DOX-treated mice. All data are presented as the mean ± SD.
Emphasizing this hypothesis, Sestrin2 has been recently proposed as a leucine sensor for the
mTORC1 pathway, since high Sestrin2 levels inhibit mTORC1 activity when intracellular leucine
concentrations are low [37]. Conversely, either low Sestrin2 levels or high intracellular leucine
concentrations—displacing Sestrin2 from the mTORC1 inhibitor GATOR2—promote mTORC1
activation [37]. Given that the α5 formula contains high leucine quantity, we measured Sestrin2
expression in our conditions. As expected from our mTORC1 results and confirming Li et al.’s recent
findings [38], DOX treatment markedly increased Sestrin2 mRNA in the left ventricle (Figure 6E).
Notably, α5 fully prevented this DOX-induced effect, although unable to change Sestrin2 expression
when supplemented alone (Figure 6E).
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Similarly, Krüppel-like factor 15 (KLF15) has recently emerged as a critical transcriptional regulator
of amino acid metabolism, particularly BCAA catabolism (i.e., the BCAA oxidation with production
of acetyl-CoA and succinyl-CoA, two TCA intermediates), especially in the heart [39], as well as an
inducer of eNOS expression in endothelial cells [40]. Thus, we studied the KLF15 expression in the left
ventricle of our different treatment groups. Klf15 mRNA levels were significantly reduced by DOX
treatment, and this reduction was fully prevented by the α5 supplementation (Figure 6F). No significant
changes were observed when α5 was supplemented alone (Figure 6F). Given the expression or activity
of mitochondrial BCAA catabolic enzymes, such as the branched-chain α-keto acid dehydrogenase
(BCKDH) complex, in the cardiac tissue is reduced in Klf15-null mice and heart failure [41,42],
we investigated the BCKDH protein transcript, in addition to the BCKDH phosphorylation in the
DOX-treated animals. When phosphorylated in fact BCKDH is inactive, while conversely when
dephosphorylated it is active [43,44]. Notably, the (Ser293)-BCKDH phosphorylation was unchanged
in DOX-treated compared to saline-treated mice, while α5 supplementation markedly reduced it
in the presence of DOX, with an inhibitory trend effect also when supplemented alone (Figure 6G).
Together, these results suggested that in vivo protection of mitochondrial homeostasis in cardiac tissue
by α5 supplementation might be related to a KLF15/eNOS/mTORC1 signaling axis, entailing the
BCAA catabolism.
To investigate more this hypothesis and to verify our findings specifically in cardiomyocytes, we
sought to assess the impact of KLF15, eNOS, and mTORC1 on mitochondrial homeostasis in HL-1
cells exposed to DOX and α5. First, although eNOS gene expression was only slightly decreased by 1
µM DOX exposure, (Ser1177)-eNOS phosphorylation was markedly reduced (Figure 7 A,B). α5 (1%
w/v) fully antagonized both DOX inhibitory effects, massively upregulating eNOS expression also
when supplemented alone (Figure 5A,B). Second, the (Ser235/236)-S6 phosphorylation was markedly
decreased by DOX, and this reduction was fully antagonized by α5 (Figure 7C). Conversely, the
amino-acid mixture was ineffective when added alone. In accordance to its role as mTORC1 controller,
Sestrin2 expression was markedly increased by DOX, and this increase was fully antagonized by the α5
supplementation (Figure 7D). The amino-acid mixture was ineffective when added alone. Third, based
on the modulatory role of Akt, also known as protein kinase B (PKB), on both eNOS and mTORC1
activation [35], we studied also the (Ser 473)-Akt phosphorylation in HL-1 cells treated with DOX and
α5. DOX markedly reduced Akt phosphorylation, while α5 prevented this effect (Figure 7E). Since
the Akt/PKB signaling pathway was recently found to mediate the effect of BCAAs on the KLF15
expression [45,46], we investigated the role of this transcription regulator in the protective impact of α5
supplement on the DOX-mediated mitochondrial damage. Notably, the KLF15 expression was reduced
both at mRNA and protein levels when HL-1 cells were exposed to DOX, and α5 fully antagonized
this effect (Figure 7F). Only a slight, not statistically significant increase of KLF15 expression was seen
in HL-1 cardiomyocytes exposed to α5 alone (Figure 7F).
The HL-1 cells were then transfected with either specific Klf15 siRNA or nontargeting siRNA.
The silencing efficacy was measured both at mRNA and protein levels (Figure S3).
DOX exposure significantly decreased both PGC-1α and COX IV protein in Klf15 siRNA-transfected
or otherwise untreated cells (Figure 7G). Conversely, the Klf15 knockdown markedly reduced PGC1-α
and COX IV levels per se and abolished the ability of α5 supplementation to rescue the protein levels
when administered with DOX (Figure 7G). Moreover, the Klf15 knockdown markedly reduced the
ability of α5 to promote PGC1-α and COX IV expression when α5 was added alone (Figure 7G).
Noteworthy, the Klf15 knockdown massively impaired the ability of α5 to restore the DOX-reduced
(Ser235/236)-S6 phosphorylation (Figure 7H). Finally, while (Ser293)-BCKDH phosphorylation was
not different between DOX-treated and untreated control HL-1 cardiomyocytes, p-BCKDH fully
disappeared when the cells were exposed to α5, with or without DOX (Figure 7H). Klf15 knockdown
partially prevented the inhibitory effect ofα5 on (Ser293)-BCKDH phosphorylation both in DOX-treated
and untreated cells, while DOX was unable to change phosphorylation when added alone (Figure 7H).
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Figure 7. Different signaling pathways are implicated in the protective effects of α5 supplementation in
DOX-treated HL-1 cardiomyocytes. (A, D, and F) Gene expression. (A) eNOS, (D) Sestrin2, (F) KLF15
mRNA levels were analysed by quantitative RT-PCR. Relative expression values for the untreated
(CTRL) cells were taken as 1.0 (n = 5 experiments). (B, C, E–H) Protein levels. (B) Phospho-eNOS,
(C) phospho-S6, (E) phospho-Akt, (F) KLF15, (G) PGC-1α and COXIV, and (H) phospho-S6 and
phospho-BCKDH protein levels were detected by immunoblot analysis. The relative values were
densitometrically analyzed and reported as ratios to total eNOS, S6, Akt, and BCKDH levels, respectively;
KLF15, PGC-1α, and COXIV were normalized to GAPDH. Values for untreated HL-1 cells were taken
as 1.0 (n = 5 experiments). (G) PGC1-α and COX IV protein levels were measured by immunoblot
analysis in HL-1 cells transfected with either specific KLF15 siRNA or nontargeting siRNA, and treated
with DOX or α5 alone or in combination. Values for untreated HL-1 cells were taken as 1.0 (n = 5
experiments). (H) S6 and BCKDH phosphorylation was measured by immunoblot analysis in HL-1
cells as in (H). * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. untreated cells; † p < 0.05 vs. DOX-treated cells.
All data are presented as the mean ± SD.
Similarly, silencing of eNOS and Raptor—one of the scaffold proteins of mTORC1
(regulatory-associated protein of mTOR)—with specific siRNAs reduced PGC1-α and COX IV levels
per se and abolished the ability of α5 supplementation to rescue the reduced protein levels when
administered with DOX (Figure S4A,B). Both eNOS and Raptor knockdown did not change PGC1-α
and COX IV expression when α5 was added alone (Figure S4A,B). The efficacy of specific silencing
was evaluated by RT-PCR and Western blot; nearly 70% and 60% down-regulation of eNOS and
mTORC1 were obtained with eNOS and Raptor siRNA, respectively (Figure S3B,C). Overall, these
findings suggest that the protective effects of α5 mixture on DOX-mediated mitochondrial dysfunction
in cardiomyocytes could be related to a KLF15/eNOS/mTORC1 signaling axis and BCAA catabolism.
Nutrients 2020, 12, 282 14 of 20
4. Discussion
Although the anthracycline DOX (trade name Adriamycin) is a highly effective and frequently used
antineoplastic drug since its introduction in the 1960s, it causes a dose-related cardiotoxicity that can
lead to severe heart failure. If the heart has been damaged by DOX, treatment options are few. Typically,
DOX-induced cardiomyopathy and heart failure are refractory to conventional therapy [2]. Increasing
efforts to predict which patients will be affected by DOX cardiotoxicity—including analysis of the
patient-specific human induced pluripotent stem cell-derived cardiomyocytes—and to appropriately
prevent this risk, encompassing drugs, such as iron-chelating agents, angiotensin-converting enzyme
inhibitors, β-blockers, antioxidants, and natural products or food supplements, have been proposed
inconclusively [47,48]. Here, we have compared the efficacy of α5, a new formula of essential
amino acids, TCA intermediates, and co-factors to BCAAem—an amino-acid mixture able to promote
mitochondrial biogenesis and anti-ROS protection in cardiac and skeletal muscle of middle-aged
mice [14]—in preventing the DOX-induced mitochondrial damage in cultured HL-1 cardiomyocytes.
α5 was statistically more efficient than BCAAem to counteract the DOX-induced deficit of mitochondrial
biogenesis markers. We did not investigate whether α5 supplementation was able to change the amino
acid and TCA intermediate levels both in cardiomyocyte and heart tissue; this could add relevant
insights on the mechanism of action of our original formula.
Further studies better aimed at quantifying metabolic changes in the heart will integrate the
biochemical and functional data reported in the present study. Examining mechanistically our findings
in cardiomyocytes and extending them in vivo, we found that the dietary supplementation of α5
activates a KLF15/Akt/eNOS/mTORC1 signaling axis (Figure 8). These results also do not exclude
a role of mTORC2, a signaling pathway that seems to be essential for normal cardiac development
and for the maintenance of postnatal cardiac structure and function—especially to adapt to stress
conditions [49]. However, mTORC2 has not been until now implied, at our knowledge, in the
DOX cardiotoxicity. Moreover, the present findings on KLF15 and Sestrin2 similarly cast doubt
on the relevance of mTORC2 signaling in this experimental model. One of the most relevant
findings of the present work is the massive downregulation of PGC-1α and COX-IV protein—that
are mitochondrial biogenesis markers—induced by the KLF15 silencing in HL-1 cardiomyocytes. The
Kruppel-like factors (KLF) family of Cys2/His2 zinc-finger transcriptional regulators control many
aspects of cardiomyocyte and mitochondrial structure and function [39]. Importantly, KLF15 regulates
Wnt/β-catenin transcription and controls cardiac progenitor cell fate in the postnatal heart, suggesting
a role in cardiac development [50]. Moreover, grossly enlarged mitochondria (or megamitochondria)
were recently found in heart of systemic and cardiac-specific Klf15-null mice, with clear evidence that
deletion of Klf15 interferes with mitochondrial fission, whereas fusion appears to be unaffected. This
was accompanied by a specific impairment of cardiac function upon fasting [51].
We have shown here that the Klf15-, eNOS-, and Raptor-silenced cardiomyocytes were unresponsive
to α5, which was unable to promote mitochondrial biogenesis per se and to protect the mitochondrial
damage when supplemented with DOX. Moreover, we found—for the first time at our best
knowledge—that after a 72-h treatment with DOX the Klf15 gene expression was reduced in cardiac
tissue. Intriguingly, KLF15 is expressed with circadian rhythmicity, being regulated by a core clock
machinery that functions in the absence of external cues, including light [52], and transcriptionally
coordinates rhythmic expression of multiple enzymes involved in amino acid metabolism [39].
The Klf15-null mice in fact exhibit reduced expression of diverse amino-acid catabolic enzymes,
including alanine amino-transferase 1, proline dehydrogenase, tryptophan 2,3-dioxygenase, and
4-hydroxyphenylpyruvic acid dioxygenase [39]. KLF15 is especially crucial for diurnal rhythms
of the release, uptake, and utilization of BCAAs in the heart [39]. Importantly, in the Klf15-null
mice, cardiac pathologies are observed, such as cardiac hypertrophy and fibrosis, which suggest
that KLF15 controls protein synthesis and proteolysis, likely through the regulation of the BCAA
homeostasis [53,54]. Recently, Sun et al. found that a reduced KLF15 expression promoted a
loss of enzymes crucial to the BCAA oxidation (e.g., BCAT2, BCKDH, and PP2Cm), resulting
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in accumulation of branched-chain ketoacids that, in turn, negatively impact on mitochondrial
function [41]. Accordingly, the pharmacological increase of the BCAA catabolism—obtained with
BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid), an inhibitor of BCHDH kinase which limiting
the BCKDH phosphorylation promotes its catabolic activity—significantly protected heart integrity
and function in mice subjected to transverse aortic constriction [41]. In this regard, the essential
amino acids and, particularly, BCAAs are known to potentiate the BCKDH catabolic activity, probably
through the stimulation of mitochondrial protein phosphatase 2C (PP2Cm) and inhibition of BCKDH
kinase [55]. Moreover, the oral administration of leucine activates the mouse cardiac BCKDH complex
and increases cardiac levels of both leucine and α-ketoisocaproate—a metabolic intermediate of
leucine oxidation [43]. Additionally, the same authors reported that the mTORC1 inhibitor rapamycin
suppressed the leucine-induced BCKDH activation, even if the cardiac leucine and α-ketoisocaproate
were increased as in rapamycin-untreated mice. These results suggest that mTORC1 plays a role
in regulating cardiac BCAA catabolism, and are consistent with our present findings. The α5
supplementation in fact prevents mitochondrial dysfunction induced by acute DOX by promoting
1) mitochondrial biogenesis, 2) anti-ROS defense system, and 3) BCAA oxidation, with a probable
production of TCA intermediates, apparently in an mTORC1-dependent manner (Figure 8).
Figure 8. A proposed model of α5 protective actions on mitochondrial damage induced by doxorubicin
(DOX) in cardiomyocytes. Plus (+) and minus (−) symbol in red colour indicate stimulation or inhibition
induced by DOX and, potentially, the α5 target sites. DOX reduces mitochondrial biogenesis and
function, (1) binding to topoisomerase IIβ (TOP2B), which complexes to the promoters of Ppargc1a
and Ppargc1b and blocks transcription of mitochondrial genes, including ROS defense genes, (2)
reducing eNOS expression and mTORC1 activity—which are important regulators of mitochondrial
physiology, (3) limiting KLF15 gene expression and presumably BCAA oxidation, with α-ketoacid
and BCAA accumulation—which are toxic at high levels—beyond reduced TCA cycle intermediates
and mitochondrial energy production. Mitochondrial accumulation of DOX is accompanied by
increased ROS.
The Klf15-knockdown in fact markedly reduced the mTORC1 activity in HL-1 cells and impaired
the ability of α5 mixture to restore the DOX-compromised S6 phosphorylation. Similarly, the Klf15
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silencing partially prevented the α5-induced activation of BCAA catabolism—measured as BCKDH
phosphorylation—both in DOX-treated and untreated cardiomyocytes. This suggests that in cardiac
cells the protective effect of α5 is mediated, at least in part, by the mTORC1 activation, that depends
on the KLF15 expression and, thus, on the BCAA oxidation. In accord with our findings, the
KLF15 deficiency was found to inhibit the amino acid-dependent mTORC1 activation also in primary
hepatocytes [56]. Moreover, we showed that in cardiac cells and tissue α5 restored to control levels
Sestrin2, which is highly expressed after DOX treatment [38]. Sestrins are a family of stress-inducible
proteins (Sestrin1–3) and a variety of evidence indicates that Sestrin2 is a leucine sensor for the mTORC1
pathway. Normally bound to GATOR2, which is thus inhibited under unstressed conditions, Sestrin2 is
displaced from GATOR2 when leucine is present at micromolar intracellular concentrations, activating
mTORC1 [37]. Mice with genetic ablation of Sestrin2 have been recently found more vulnerable to the
DOX-induced cardiac dysfunction, associated with an activation of the mTORC1 pathway, suggesting
that Sestrin2 is an important cardioprotective protein to preserve at balanced levels [38]. The here
described ability to modulate Sestrin2 expression thus could strengthen the rationale for dietary α5
supplementation to prevent and perhaps treat the DOX cardiotoxicity.
This therapeutic rationale is supported further by the observation that ourα5 formula promoted the
eNOS expression and activity, in both DOX-treated and untreated cardiac cells and tissue. Probably these
effects were mediated by (Ser473)-Akt phosphorylation. An extensive scientific literature demonstrates
that the Akt-eNOS activation with drugs and food supplements mitigates the DOX-induced cardiac
damage both in animals and humans [57–62]. Given that in endothelial cells KLF15 is a clock-dependent
peripheral oscillator that controls eNOS expression [40], our present findings suggest that cardiac
sensitivity to both DOX and α5 could be regulated by circadian rhythms and, thus, might need to
be timely administered during the day to function at best. The role of clock proteins (e.g., Per2 and
BMAL1) has been recently proposed in DOX-induced cell death and breast cancer [63,64].
A limit of the present study is the lack of in vivo measurements of heart physiology in mice
treated with DOX and α5. Our principal purpose, however, was to first assess the ability of the novel
α5 formula to prevent the cardiac mitochondrial damage induced by DOX and to characterize the
molecular mechanisms involved. Our results offer to study cardiac activity with more adequate coming
in vivo studies. A second limit of this study is the absence of exploration on the neoplastic potential
of α5, although this seems to be cast doubt by increasing evidence that supplementation of amino
acids—especially the BCAAs—is beneficial mainly in liver cancer, yet their role in the nutritional
support of cancer patients remains to be clearly defined [65–69]. Similarly, we did not investigate with
appropriate in vivo models whether the α5 supplementation can affect the antineoplastic efficacy of
DOX. Nevertheless, the exposure of MCF7 breast cancer cell line to α5 mixture did not promote MCF7
cell proliferation, as assessed with two different assays (Figure S5A,B). Similarly, the anti-proliferative
effect of DOX in MCF7 cells was completely unaffected by the amino acid presence (Figure S5A,B).
5. Conclusions
Overall, our findings: (1) confirm that acute DOX treatment induces mitochondrial dysfunction
in both cardiac tissue and cardiomyocytes, (2) demonstrate that a designer amino acid formula, that
we named α5—after five abundances, among TCA intermediates and co-factors—markedly prevents
this damage, (3) suggest that eNOS and mTORC1 signaling pathways are crucially involved in the
action of this protector, and (4) show that KLF15, a specific transcription factor particularly important
in cardiac development and circadian regulation, plays a relevant role in controlling these signaling
axis. These findings highlight that dietary α5 supplementation might be a strategy in DOX-treated
patients to prevent cardiomyopathy, acting on a complex signaling network.
Supplementary Materials: The following are available online at http://www.mdpi.com/xxx/s1: Figure S1: TCA
intermediates do not prevent DOX-induced reduction of mitochondrial biogenesis genes in HL-1 cardiomyocytes;
Figure S2: α5 formula prevents DOX-induced death of HL-1 cells; Figure S3: specific Klf15, eNOS, and Raptor
silencing in HL-1 cardiomyocytes; Figure S4: specific eNOS and Raptor silencing abolishes the protective effect
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of α5 on DOX-induced toxicity in HL-1 cardiomyocytes; Figure S5: MCF7 breast cancer cell proliferation.
The anti-proliferative effect of DOX remained unchanged in the MCF7 cells in the presence of the amino
acid mixture.
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